Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has been granted $50,000 non-repayable funds by National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support development of IL-17E for cancer therapy.
Subscribe to our email newsletter
The NRC researchers will use the money for a pilot development project to manufacture IL-17E.
The NRC-IRAP funds will also allow Lorus to access knowledge and capabilities combined with the required technical equipment.
The project aims to supply technical manufacturing development and pilot scale production for IND-enabling studies to produce IL-17E for cancer clinical trials.
Lorus president and CEO Aiping Young said IL-17E has shown anti-cancer activity in cancer types in preclinical studies and the NRC-IRAP support, both in providing technical and business advisory services as well as funding further verifies the merits of this development program.
"This support will expedite the development of initial manufacturing protocols for our development program and move us closer to initiating the studies needed to support first-in-man clinical trials with this exciting therapy," Young added.
IL-17E, a cytokine, has potent anticancer properties against solid tumors, including human melanoma, pancreatic, colon, lung, ovarian and breast tumor models with very low toxicity.